Qiagen NV (QGEN) shares plummeted 5.30% in intraday trading, despite the company reporting better-than-expected third-quarter results. The sharp decline comes as the biotechnology provider announced a series of significant developments, including the departure of its CEO, a major acquisition, and a substantial share repurchase program.

In its Q3 earnings report, Qiagen beat analyst expectations with quarterly earnings of $0.61 per share, surpassing the consensus estimate of $0.59. The company also reported sales of $533 million, exceeding the projected $525.929 million. To further boost shareholder value, Qiagen announced plans to return approximately $500 million to shareholders through a synthetic share repurchase, combining a direct capital repayment with a reverse stock split.

However, the positive financial news was overshadowed by the announcement that CEO Thierry Bernard plans to step down after six years at the helm. Bernard will remain in his role until a successor is appointed, with the company's Supervisory Board initiating a search for both internal and external candidates. Additionally, Qiagen revealed its intention to acquire Parse Biosciences, a provider of scalable, instrument-free solutions, for up to $280 million. While this acquisition aims to strengthen Qiagen's sample technologies portfolio, investors appear to be reacting cautiously to the leadership change and the financial implications of the acquisition, contributing to the stock's significant decline.